Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR Mind Medicine Inc (MMQ.MU) Follow Add holdings 5.47 -0.18 (-3.23%) At close: April 25 at 9:55:00 PM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for MMQ.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: MMQ.MU View More All News Press Releases SEC Filings MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) MindMed Announces New Employee Inducement Grants MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) Psychedelic: Exclusive talk with biotech company Clearmind Medicine Psychedelic: atai Life Sciences, NRx report quarterly results MindMed Appoints Matt Wiley as Chief Commercial Officer Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates MindMed to Present at Leerink’s Global Healthcare Conference 2025 Psychedelic: GH Research, Compass Pathways report earnings results